Baohuoside I inhibits virulence of multidrug-resistant Staphylococcus aureus by targeting the transcription Staphylococcus accessory regulator factor SarZ
- PMID: 38810547
- DOI: 10.1016/j.phymed.2024.155590
Baohuoside I inhibits virulence of multidrug-resistant Staphylococcus aureus by targeting the transcription Staphylococcus accessory regulator factor SarZ
Abstract
Background: Staphylococcus aureus is a versatile pathogen that can cause a wide range of infections in humans. Biofilms play a crucial role in the pathogenicity of S. aureus and contribute to its ability to cause persistent and chronic infections. Baohuoside I has garnered increasing recognition as a natural flavonol glycoside with a wide spectrum of health-related activities.
Purpose: The antibacterial and anti-biofilm properties of Baohuoside I have not been extensively investigated. Our study aimed to assess its inhibitory effects and the underlying mechanisms on biofilm formation and hemolytic capacity in S. aureus.
Study design/methods: The impact of Baohuoside I on the biofilm and virulence of S. aureus was evaluated through in vitro experiments and Galleria mellonella as an in vivo infection model. The mechanisms were explored by Drug affinity responsive target stability (DARTS) and validated in genetic knockout strain and through molecular biological experiments using DARTS, molecular docking, electrophoretic mobility shift assay (EMSA), and bio-layer interferometry (BLI).
Results: Baohuoside I significantly inhibits the formation of S. aureus biofilms and hemolytic activity at 6.25 µM. Proteomics analysis revealed that treatment with Baohuoside I led to a reduction in the expression of quorum-sensing system agr-regulated genes. DARTS analysis identified Staphylococcus accessory regulator factor (SarZ), a key regulator involved in the expression of virulence factors in S. aureus by acting as activator of the agr quorum-sensing system, was the direct target of Baohuoside I. Molecular docking, DARTS, BLI and EMSA assays collectively confirmed the direct binding of Baohuoside I to SarZ, inhibiting its binding to downstream promoters. Furthermore, it is found through site-directed protein mutagenesis that the Tyr27 and Phe117 residues are key for Baohuoside I binding to SarZ. Additionally, the knockout of SarZ significantly diminished the hemolytic ability of S. aureus, underscoring its crucial role as a pivotal regulator of virulence. Lastly, in vivo tests utilizing the G. mellonella infection model demonstrated the efficacy of Baohuoside I.
Conclusion: This study provides valuable insights into the mechanism by which Baohuoside I inhibits the virulence of S. aureus through its interaction with SarZ. These findings highlight the significance of SarZ as an effective target against the virulence of S. aureus.
Keywords: Baohuoside I; SarZ; Staphylococcus aureus; agr quorum-sensing system; biofilm; virulence.
Copyright © 2024. Published by Elsevier GmbH.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Baohuoside I targets SaeR as an antivirulence strategy to disrupt MRSA biofilm formation and pathogenicity.NPJ Biofilms Microbiomes. 2025 Mar 19;11(1):45. doi: 10.1038/s41522-025-00681-2. NPJ Biofilms Microbiomes. 2025. PMID: 40102466 Free PMC article.
-
Quercetin combined with ciprofloxacin and gentamicin inhibits biofilm formation and virulence in Staphylococcus aureus.Microb Pathog. 2025 Mar;200:107297. doi: 10.1016/j.micpath.2025.107297. Epub 2025 Jan 13. Microb Pathog. 2025. PMID: 39814109
-
Unraveling the efficacy of verbascoside in thwarting MRSA pathogenicity by targeting sortase A.Appl Microbiol Biotechnol. 2024 Jun 5;108(1):360. doi: 10.1007/s00253-024-13202-6. Appl Microbiol Biotechnol. 2024. PMID: 38836914 Free PMC article.
-
Disarming Staphylococcus aureus: Review of Strategies Combating This Resilient Pathogen by Targeting Its Virulence.Pathogens. 2025 Apr 15;14(4):386. doi: 10.3390/pathogens14040386. Pathogens. 2025. PMID: 40333163 Free PMC article. Review.
-
Investigational therapies targeting quorum-sensing for the treatment of Staphylococcus aureus infections.Expert Opin Investig Drugs. 2015 May;24(5):689-704. doi: 10.1517/13543784.2015.1019062. Epub 2015 Feb 23. Expert Opin Investig Drugs. 2015. PMID: 25704585 Free PMC article. Review.
Cited by
-
Repurposing AZD-5991 for inhibiting growth and biofilm formation of Staphylococcus aureus by disrupting the cell membrane and targeting FabI.BMC Microbiol. 2025 Jul 2;25(1):393. doi: 10.1186/s12866-025-04104-2. BMC Microbiol. 2025. PMID: 40604387 Free PMC article.
-
Repurposing Etalocib suppresses multidrug-resistant Staphylococcus aureus by disrupting the bacterial membrane.BMC Microbiol. 2025 Aug 1;25(1):472. doi: 10.1186/s12866-025-04163-5. BMC Microbiol. 2025. PMID: 40750851 Free PMC article.
-
Klebsiella pneumoniae under xylose pressure: the growth adaptation, antimicrobial susceptibility, global proteomics analysis and role of XylA and XylB proteins.BMC Microbiol. 2025 Apr 29;25(1):257. doi: 10.1186/s12866-025-03961-1. BMC Microbiol. 2025. PMID: 40301709 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical